

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934.

Date of Report: March 18, 2009
(Date of earliest event reported)

Oragenics, Inc

(Exact name of registrant as specified in its charter)

FL
(State or other jurisdiction
of incorporation)

001-38122
(Commission File Number)

59-3410522
(IRS Employer
Identification Number)

13700 Progress Blvd
(Address of principal executive offices)

32615
(Zip Code)

386-418-4018
(Registrant's telephone number, including area code)

Not Applicable
(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; APPOINTMENT OF CERTAIN OFFICER;
COMPENSATORY ARRANGEMENT OF CERTAIN OFFICER**

Effective March 18, 2009, Mr. Stanley B. Stein resigned as President, Chief Executive Officer and director of the Company, but will thereafter continue to provide services to the Company as an advisor. Mr. Stein's resignation was not due to any disagreement with the Company on any matter related to its operations, policies or practices.

Mr. Stein and the Company have simultaneously entered into a Separation Agreement which ended his duties as an employee and director of the Company and entered into a Consulting Agreement pursuant to which Mr. Stein will continue to provide services to the Company on an as needed basis. The Consulting Agreement is effective March 18, 2009.

David Hirsch the Company's Chief Financial Officer and Chief Operating Officer will serve as the acting Chief Executive Officer and Dr. Robert T. Zahradnik, Ph.D., the Company's Vice President of Business Development will serve as acting Chief Operating Officer. Mr. Hirsch's and Dr. Zahradnik's current employment arrangements with the Company will remain in effect without alteration to its financial terms. Mr. Hirsch's financial arrangement has been previously disclosed. Dr. Zahradnik's financial arrangement provides for an annual salary of \$50,000 and a grant of 150,000 stock options that are to be vested in three events of 50,000 shares each based on certain future milestones.

A copy of the March 19, 2009 press release announcing the resignation of Mr. Stein as president, chief executive officer and director is attached to this report as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 FINANCIAL INFORMATION AND EXHIBITS

(c) Exhibits.

<u>Number</u>	<u>Description</u>
99.1	Press Release dated March 19, 2009

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 19th day of March, 2009.

ORAGENICS, INC.
(Registrant)

BY: /s/ David Hirsch
David Hirsch
Chief Financial Officer

FOR IMMEDIATE RELEASE

March 19, 2009

Oragenics, Inc. Announces Management Changes

(Alachua, FL)-March 19, 2009- Oragenics, Inc. (OTCBB: ORNI) today announced that Stanley B. Stein resigned as President, Chief Executive Officer and director of Oragenics, Inc.(the "Company"), effective yesterday and will thereafter continue to provide services to the Company as an advisor. Mr. Stein's resignation is not due to any disagreement with the Company on any matter related to its operations, policies, and practices.

David Hirsch, the Company's Chief Financial Officer and Chief Operating Officer, will assume additional responsibilities as acting Chief Executive Officer and Dr. Robert T. Zahradnik, PhD., the Company's Vice President of Business Development, will assume the role of acting Chief Operating Officer formerly served by Mr. Hirsch.

Richard T. Welch, Chairman of the Board, commented "We look forward to continuing to work with Stan in certain select matters relating to strategic alternatives, business development and capital strategies. Also, the Board is very confident that David Hirsch has the requisite skill sets to effectively lead the Company at this time and continue to move things forward in a very exciting year for the Company".

About Oragenics, Inc.

Oragenics, Inc., is a biopharmaceutical company engaged in developing unique proprietary technologies, some of which are being commercialized and sold in the over-the-counter consumer healthcare market. The company also has a number of products in discovery, preclinical and clinical development, with a concentration in the main therapeutic area of infectious diseases, diagnostics, and oral health. The company is located in Progress Corporate Park at 13700 Progress Boulevard in Alachua, Florida, approximately 15 miles from the campus of the University of Florida in Gainesville.

***Safe Harbor Statement:** Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect the Company's current views with respect to future events and financial performance. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to those set forth in our most recently filed annual report on Form 10-KSB and quarterly report on Form 10-Q, and other factors detailed from time to time in filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.*

CONTACT

David Hirsch, CEO and CFO, Oragenics, Inc.
386-418-4018, Ext. 232 -- dhirsch@oragenics.com
